Claims
- 1. A method for reducing self-administration of alcohol in a patient suffering from alcoholism comprising administering to said patient a therapeutically effective amount of an NPY receptor antagonist and determining the level of alcohol self-administration in said patient before and after said administering.
- 2. The method according to claim 1, wherein said NPY receptor antagonist is a selective NPY Y1 receptor antagonist.
- 3. The method according to claim 2, wherein said selective NPY Y1 receptor antagonist is BIBP 3226.
- 4. The method according to claim 1, wherein said NPY receptor antagonist is a selective NPY Y5 receptor antagonist.
- 5. The method according to claim 4, wherein said NPY receptor antagonist is 2-(3,3-dimethyl-1-oxo-4H-1H-xanthen-9-yl)-5,5-dimethyl-cyclohexane-1,3-dione or a pharmaceutically acceptable salt or hydrate thereof.
- 6. A method for reducing alcohol-seeking behavior in a patient suffering from alcoholism comprising administering to said patient a therapeutically effective amount of an NPY receptor antagonist and determining the level of alcohol-seeking behavior in said patient before and after said administering.
- 7. The method according to claim 6, wherein said NPY receptor antagonist is a selective NPY Y1 receptor antagonist.
- 8. The method according to claim 7, wherein said selective NPY Y1 receptor antagonist is BIBP 3226.
- 9. The method according to claim 6, wherein said NPY receptor antagonist is a selective NPY Y5 receptor antagonist.
- 10. The method according to claim 9, wherein said NPY receptor antagonist is 2-(3,3-dimethyl-1-oxo-4H-1H-xanthen-9-yl)-5,5-dimethyl-cyclohexane-1,3-dione or a pharmaceutically acceptable salt or hydrate thereof.
- 11. A method for preventing or reducing the occurrence of relapse drinking in a recovering alcoholic patient comprising administering to said patient a therapeutically effective amount of an NPY receptor antagonist and determining the frequency of occurrence of relapse drinking in said patient before and after said administering.
- 12. The method according to claim 11, wherein said NPY receptor antagonist is a selective NPY Y1 receptor antagonist.
- 13. The method according to claim 12, wherein said selective NPY Y1 receptor antagonist is BIBP 3226.
- 14. The method according to claim 11, wherein said NPY receptor antagonist is a selective NPY Y5 receptor antagonist.
- 15. The method according to claim 14, wherein said NPY receptor antagonist is 2-(3,3-dimethyl-1-oxo-4H-1H-xanthen-9-yl)-5,5-dimethyl-cyclohexane-1,3-dione or a pharmaceutically acceptable salt or hydrate thereof.
- 16. A pharmaceutical composition for the treatment of alcoholism in a mammal afflicted therewith comprising a therapeutically effective amount of an NPY receptor antagonist.
Priority Claims (1)
Number |
Date |
Country |
Kind |
60237964 |
Oct 2000 |
US |
|
ACKNOWLEDGEMENTS
[0001] This invention was supported in part by grant #AA1 1854 from the National Institutes of Health. The U.S. Government may have rights in this invention.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/US01/30830 |
10/2/2001 |
WO |
|